放疗对非小细胞肺癌患者循环内皮祖细胞数量和功能的影响

中国核心期刊（遴选）数据库收录期刊
中文科技期刊数据库收录期刊
中国期刊全文数据库收录期刊
中国学术期刊综合评价数据库统计源期刊等

快速检索引用检索图表检索高级检索

• 投稿 • 下一篇

放疗对非小细胞肺癌患者循环内皮祖细胞数量和功能的影响

刘海峰,毛丽梅,王海彦,胡丽娜

作者单位：252000 山东省聊城市人民医院保健科刘海峰、毛丽梅、王海彦,潍坊市人民医院感染性疾病科胡丽娜,作者单位：252000 山东省聊城市人民医院保健科刘海峰、毛丽梅、王海彦,潍坊市人民医院感染性疾病科胡丽娜,作者单位：252000 山东省聊城市人民医院保健科刘海峰、毛丽梅、王海彦,潍坊市人民医院感染性疾病科胡丽娜,作者单位：252000 山东省聊城市人民医院保健科刘海峰、毛丽梅、王海彦,潍坊市人民医院感染性疾病科胡丽娜

收稿日期:2018-08-13 修回日期:2018-09-27 出版日期:2018-09-25
基金资助:
山东省医药卫生科技发展计划（保健项目）资助课题(项目编号：2015WSC02017；项目名称：放射性肺损伤患者外周血内皮祖细胞数量和功能的变化）

Effect of Radiotherapy on the Number and Function of Circulating Endothelial Progenitor Cells in the Patients with Non-small Cell Lung Cancer

LIU Haifeng,MAO Limei,WANG Haiyang and HU Lina

Liaocheng People’s Hospital,Liaocheng People’s Hospital,Liaocheng People’s Hospital,Liaocheng People’s Hospital

Received:2018-08-13 Revised:2018-09-27 Online:2018-09-25

摘要/Abstract

摘要： 目的：检测非小细胞肺癌（non-small cell lung cancer，NSCLC）患者放疗过程中循环内皮祖细胞（circulating endothelial progenitor cells，cEPCs）数量和功能的变化，探讨放疗对cEPCs数量和功能的影响。方法：选取2015年1月至2016年5月于我院住院确诊NSCLC并选择放疗患者30例为治疗组，以同期健康体检者30例为对照组。治疗组放疗前、放疗后第15天、放疗后第30天，对照组于入组后次日抽取外周静脉血分离单个核细胞，体外培养后鉴定内皮祖细胞，并检测cEPCs数量、迁移、粘附能力。结果：NSCLC患者放疗前cEPCs数量高于对照组；cEPCs迁移、粘附能力均高于对照组，差异有统计学意义（P＜0.01）；NSCLC患者cEPCs的数量及迁移、粘附能力在放疗后各期与放疗前的差异有统计学意义（P＜0.05）；治疗组cEPCs的数量在放疗后第30天最少，差异有统计学意义（P＜0.05）；治疗组cEPCs的迁移、粘附能力在放疗后第30天最低，差异有统计学意义（P＜0.05）。结论：NSCLC患者cEPCs数量升高，迁移、粘附能力增强，放疗后cEPCs数量降低，迁移、粘附能力下降，检测cEPCs有可能作为NSCLC患者辅助诊断和评价治疗效果的指标之一。

Abstract: Objective：Changes on the number and function of circulating endothelial progenitor cells（cEPCs）after radiotherapy in patients with non-small cell lung cancer（NSCLC）were examined to investigate the impact of radiotherapy on cEPCs.Methods：Thirty patients from January 2015 to May 2016 in our hospital with NSCLC were enrolled as the treatment group， and thirty cases of health subjects as the control group at the same time. Peripheral venous blood samples of the treatment group were obtained before radiotherapy， fifteen and thirty days after radiotherapy respectively, and the samples of the control group were obtained the next day after admission. The number and function of cEPCs pre- and post-treatment were measured by density gradient centrifugation method.Results： The number of cEPCs significantly increased in patients with NSCLC compared with control subjects， and their cEPCs function of migration and adhesion ability enhanced， and the difference was statistically significant (P<0.01). In addition， cEPCs number and function of patients with NSCLC were decresed after radiotherapy， and the difference was statistically significant(P<0.05). The number and function(migration and adhesion ability) of cEPCs were decreased more thirty days after radiotherapy， and the difference was statistically significant(P<0.05). Conclusion：Radiotherapy can reduce the number of cEPCs and the migration and adhesion ability of cEPCs in patients with NSCLC.The detection of cEPCs may be one of the indicators for the adjuvant diagnosis and therapeutic effect of NSCLC patients.

刘海峰,毛丽梅,王海彦,胡丽娜. 放疗对非小细胞肺癌患者循环内皮祖细胞数量和功能的影响[J]. .

LIU Haifeng,MAO Limei,WANG Haiyang and HU Lina. Effect of Radiotherapy on the Number and Function of Circulating Endothelial Progenitor Cells in the Patients with Non-small Cell Lung Cancer[J]. .

参考文献

[1] Morgensztern D,Ng S H,Gao F,et al. Trends in stage distribution for patients with non-small cell lung cancer：a national cancer database survey[J]. J Thorac Oncol,2010,5(1)：29-33.
[2] Tyldesley S,Boyd C,Schulze K,et al. Estimating the need for radiotherapy for lung cancer：An evidence-based,epidemiologic approach[J]. Int J Radiat Oncol Biol Phys,2001,49(4)：973-985.
[3] Mund J A,Case J. The role of circulating endothelial progenitor cells in tumor angiogenesis [J]. Curr Stem Cell Res Ther,2011,6(2)：115-121.
[4] Nowak K,Rafat N,Belle S,et al. Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease [J]. Eur J Cardio thorac Surg,2010,37(4)：758-763.
[5] Marks LB,Yu X,Vugaskovic I,et al. Radiation- induced lung injury [J]. Semin Radiat Oncol,2003,13：333- 345.
[6] Tamura M,Unno K,Yonezawa S,et al. In vivo trafficking of endothelial progenitor cells their possible involvement in the tumor neovascularization [J]. Life Sci,2004,75(5)：575-584.
[7] Stou BR,Migliorini C,Kadambi A,et al. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors：implications for antiangiogenic therapy [J]. Blood,2003,102(7)：2555-2561.
[8] Yu D,Sun X,Qiu Y,et al. Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculo-genesis of hepatocellular carcinoma [J]. Clin Cancer Res,2007,13：3814.
[9] Furstenberger G,von Moos R,Lucas R,et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer [J]. Br J Cancer,2006,94：524 .
[10] Igreja C,Courinha M,Cachaco AS,et al. Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients [J]. Haematologica,2007,92：469 .
[11] Fleitas T,Martinez-sales V,Gomez-codina J,et al. Circulating endothelial and endothelial progenitor cells in non-small cell lung cancer [J]. Clin Transl Oncol,2010,12(8)：521-525.
[12] Pahmbo B,Pahmbo R,Sinzinger H. Radioidine therapy temporarily increases circulating endothelial cells and decreases endothelial progenitor cells [J]. Nucl Med Rev Cent East Eur,2003,6(2)：123-126.
[13] Brunner M,Thurnher D,Heiduschka G,et al. Elevated levels of circulating endothelial progenitor cells in head and neck cancer patients [J]. J Surg oncol,2008,98(7)：545-550.
[14] Raids M,Weiss T,Leo C,et al. Circulating endothelial progenitor cells are inversely correlated with the median oxygen tension in the tumor tissue of patients with cervical cancer [J]. Oncol Rep,2006,16(3)：597-601.
[15] Willett CG,Duda DG,Tomaso E,et al. Efficacy,safety,and biomarkers of neoadjuvant bevacizumab,radiation therapy. And fluomuracil in rectal cancer：a multidisciplinary phase Ⅱ study [J]. J Clin Oncel,2009,27(18)：3020-3026.
[15] Willett CG,Duda DG,Tomaso E,et al. Efficacy,safety,and biomarkers of neoadjuvant bevacizumab,radiation therapy. And fluomuracil in rectal cancer：a multidisciplinary phase Ⅱ study [J]. J Clin Oncel,2009,27(18)：3020-3026.
[15] Willett CG,Duda DG,Tomaso E,et al. Efficacy,safety,and biomarkers of neoadjuvant bevacizumab,radiation therapy. And fluomuracil in rectal cancer：a multidisciplinary phase Ⅱ study [J]. J Clin Oncel,2009,27(18)：3020-3026.
[15] Willett CG,Duda DG,Tomaso E,et al. Efficacy,safety,and biomarkers of neoadjuvant bevacizumab,radiation therapy. And fluomuracil in rectal cancer：a multidisciplinary phase Ⅱ study [J]. J Clin Oncel,2009,27(18)：3020-3026.
[15] Willett CG,Duda DG,Tomaso E,et al. Efficacy,safety,and biomarkers of neoadjuvant bevacizumab,radiation therapy. And fluomuracil in rectal cancer：a multidisciplinary phase Ⅱ study [J]. J Clin Oncel,2009,27(18)：3020-3026.
[15] Willett CG,Duda DG,Tomaso E,et al. Efficacy,safety,and biomarkers of neoadjuvant bevacizumab,radiation therapy. And fluomuracil in rectal cancer：a multidisciplinary phase Ⅱ study [J]. J Clin Oncel,2009,27(18)：3020-3026.

相关文章 0

编辑推荐

Metrics

本文评价